Isle of Wight NHS data to be used for research (and you can join in)
People on the Isle of Wight are being asked to help shape NHS research.
It is part of University Hospital Southampton's Improving Tomorrow's Health campaign, which addresses critical health challenges using NHS patient data.
Join the conversation online or at local events by visiting https://wessexsde.nhs.uk.
The campaign's research shows that 60 per cent of people on the Isle of Wight support the use of health data to improve the NHS.
The Wessex Secure Data Environment (SDE), a new NHS platform, aims to change this by using patient data to develop new treatments and improve NHS efficiency, effectiveness, and safety.
The SDE is a secure computing platform for storing and linking different types of NHS patient data.
It allows researchers to ask bigger questions, look at more sides of a problem, and gain new insights to come up with new treatments and technologies.
The research also shows that 62 per cent of people on the Isle of Wight support the use of their data for life-saving research.
The public's top priorities include cancer, heart and circulatory health, dementia, and mental health.
Sixty per cent of people on the Isle of Wight support the use of their data for research as long as personal details remain protected, while 63 per cent stress the importance of transparency.
Professor Christopher Kipps, Wessex SDE project lead and professor of clinical neurology and dementia at University Hospital Southampton NHS Foundation Trust, said: "The Wessex SDE accelerates breakthrough research powered by NHS patient data, but it's no easy task.
Dr Dan Bayliss, chief medical officer, Hampshire and IoW, outside Tatchbury Mount HIOW Healthcare. (Image: supplied)
"Today NHS data is fragmented – making it difficult for researchers who want to see the big picture, spot trends and make discoveries."
Dr Dan Bayliss, chief medical officer, Hampshire and IoW, said: 'The Wessex SDE is all about unlocking NHS data so that we really understand the issues that matter to the people we care for so that we can make their lives better.'
Over the next two months, the Improving Tomorrow's Health campaign invites everyone on the Isle of Wight to share their views on how NHS data should be used for research.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
World-first blood cancer therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer than current therapies. The drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing side-effects. Paul Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our bones. Paul, who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his back. He had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access scheme. Within weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the city. Myeloma cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing". He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important. "We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could benefit. The decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. The technical name for these drugs is an antibody-drug-conjugate. This therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in London. Prof Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable". While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years". Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel cancer. Shelagh McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment". Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation." Exercise improves colon cancer survival, major study shows Breakthrough cancer drug doubles survival in trial
Yahoo
8 hours ago
- Yahoo
‘Trojan horse' treatment given green light for NHS use
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP!#BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
Yahoo
12 hours ago
- Yahoo
Family doctors could run hospitals under NHS shake-up
Family doctors could run NHS hospitals under plans being considered by Wes Streeting. The Health Secretary said he would overhaul the 'traditional expectations' about how services should be run in the 10-year health plan, which is due to be published within weeks. In a speech to NHS leaders in Manchester, Mr Streeting said he was open to wholesale changes in how local NHS services operate. He said this could mean family doctors leading local hospitals and NHS hospital trusts running more patient services such as GP practices if it would improve patient care. Multiple reports, including the gold-standard British Social Attitudes Survey, have found getting a GP appointment is the public's biggest issue with the NHS. 'The NHS should not be bound by traditional expectations of how services should be arranged,' he told delegates at the NHS ConfedExpo conference. 'I am open to our strongest acute trusts providing not just community services, as many already do, but also primary care, whatever services will enable them to meet the needs of their patients in a more integrated and efficient way.' Primary care includes services such as general practice, dentistry, eye appointments and pharmacies. The 10-year health plan will lay out how the NHS can reform to become a 'neighbourhood health service' with care delivered closer to home. Moving care from hospitals to the community is one of the Government's three big shifts for the NHS, along with moving from systems of analogue to digital and treatment to prevention. Mr Streeting said he hoped such terms as acute and community care 'become increasingly meaningless' and that there was also 'no reason why successful GPs should not be able to run local hospitals, or why nurses should not be leading neighbourhood health services'. The plan will give more power to NHS foundation trusts, which were created under the last Labour government and hailed by Mr Streeting as 'one of the most successful reforms in the last 25 years'. He said it would 'reinvigorate' and 'reinvent' the model, which could now include them running GP services, and will see them take on more responsibility for how to run healthcare in their local areas. It comes after the NHS was given a record £29 billion funding injection in Wednesday's spending review, with officials declaring the health service had been the 'winner', while other public services lost out. Mr Streeting said that it was right to think 'that's a hell of a lot of money' but that think tanks were also right in saying it 'is nowhere near enough'. 'The truth is both are right. It is objectively a substantial settlement that puts wind in our sails,' he said. 'The investment alone isn't enough.' Matthew Taylor, the chief executive of the NHS Confederation, said: 'Redesigning services is essential to the future of the NHS and many providers are already breaking down their traditional silos to offer patients truly personalised and integrated care. 'The extra funding announced at the spending review is very welcome and as Mr Streeting says, it is both a lot of money and not enough,' he said. 'Our members will welcome Mr Streeting confirming he will support them to make the difficult decisions needed to redesign services. This is something we have been calling for and will be a weight off the minds of many system and provider leaders. 'We also welcome his announcement that the upcoming 10-year plan will put an end to central control and place more power into the hands of local leaders to lead and innovative to benefit their populations.' Earlier on Thursday, NHS figures revealed that the overall waiting list had fallen to 7.39 million – its lowest in two years. However, the number of people waiting longer than a year for a hospital appointment or procedure was up by about 10,000 to 190,000, having previously fallen for 10 months in a row. Waits of longer than 18 months also grew. Meghana Pandit, NHS England's co-national medical director, said NHS staff were working to 'turn the tide for patients waiting for care'. She said while huge pressure on services remains, 'we are starting to see a real difference across our services – this is just the start of the work we're doing to reform care and deliver improvements for patient'. The data also showed fewer people are getting a diagnosis of cancer or having it ruled out within four weeks. A total of 76.7 per cent of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in April, down from 78.9 per cent in March and 80.2 per cent in February. The Government and NHS England had set a target of March 2026 for this figure to reach 80 per cent. The proportion of patients who had waited no longer than 62 days in April from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 69.9 per cent, down from 71.4 per cent in March. GPs in England made 264,880 urgent cancer referrals in April, down from 272,165 in March but up year-on-year from 260,516 in April 2024. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
